Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome

Cell Mol Life Sci. 2024 May 13;81(1):215. doi: 10.1007/s00018-024-05245-9.

Abstract

Down syndrome (DS) is a genetic disease characterized by a supernumerary chromosome 21. Intellectual deficiency (ID) is one of the most prominent features of DS. Central nervous system defects lead to learning disabilities, motor and language delays, and memory impairments. At present, a prenatal treatment for the ID in DS is lacking. Subcutaneous administration of synthetic preimplantation factor (sPIF, a peptide with a range of biological functions) in a model of severe brain damage has shown neuroprotective and anti-inflammatory properties by directly targeting neurons and microglia. Here, we evaluated the effect of PIF administration during gestation and until weaning on Dp(16)1Yey mice (a mouse model of DS). Possible effects at the juvenile stage were assessed using behavioral tests and molecular and histological analyses of the brain. To test the influence of perinatal sPIF treatment at the adult stage, hippocampus-dependent memory was evaluated on postnatal day 90. Dp(16)1Yey pups showed significant behavioral impairment, with impaired neurogenesis, microglial cell activation and a low microglial cell count, and the deregulated expression of genes linked to neuroinflammation and cell cycle regulation. Treatment with sPIF restored early postnatal hippocampal neurogenesis, with beneficial effects on astrocytes, microglia, inflammation, and cell cycle markers. Moreover, treatment with sPIF restored the level of DYRK1A, a protein that is involved in cognitive impairments in DS. In line with the beneficial effects on neurogenesis, perinatal treatment with sPIF was associated with an improvement in working memory in adult Dp(16)1Yey mice. Perinatal treatment with sPIF might be an option for mitigating cognitive impairments in people with DS.

Keywords: Cyclin D1; Dp(16)1Yey mice; S100 beta; Social behavior; Vocalizations; c-myc.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cognition Disorders / drug therapy
  • Cognition Disorders / pathology
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology
  • Disease Models, Animal*
  • Down Syndrome* / complications
  • Down Syndrome* / drug therapy
  • Down Syndrome* / genetics
  • Down Syndrome* / metabolism
  • Down Syndrome* / pathology
  • Dyrk Kinases
  • Female
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Male
  • Mice
  • Microglia / drug effects
  • Microglia / metabolism
  • Microglia / pathology
  • Neurogenesis* / drug effects
  • Pregnancy
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism

Substances

  • Protein Serine-Threonine Kinases
  • Protein-Tyrosine Kinases
  • Dyrk Kinases